Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2012-11-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于将募投项目“国际化制剂项目”变更为“高技术针剂示范项目”的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the change of a fundraising investment project from 'International Formulation Project' to 'High-tech Injection Demonstration Project'. It details the original and changed project investment amounts, construction content, funding sources, and approvals by the board and supervisory committee. The document is a formal announcement about a change in the use of raised funds and the project plan, including approvals and opinions from the board, independent directors, supervisory committee, and sponsor institution. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, audit report, or legal proceeding. It is not a report publication announcement since it contains substantive content about the project change. The document fits best under Capital/Financing Update (CAP) as it relates to changes in fundraising project use and capital allocation.
2012-11-01 Chinese
2012年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2012 fourth extraordinary shareholders' meeting of Kunming Pharmaceutical Group Co., Ltd. It details the voting results for the election of board and supervisory board candidates, with unanimous approval. The document includes information about the meeting's convening, attendance, and legal witness statements confirming the legality of the meeting and voting procedures. There is no financial data or detailed report content; rather, it is an official announcement of voting results from a shareholders' meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2414 characters, which is consistent with an announcement rather than a full report or presentation.
2012-11-01 Chinese
对外担保公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding an external guarantee provided to its wholly-owned subsidiary. It details the guarantee amount, terms, and the board's opinion on the guarantee. The document is short (1430 characters) and focuses on a specific financing-related event (providing a loan guarantee). It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. It is an announcement about a capital/financing activity (loan guarantee). Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-11-01 Chinese
七届二次董事会决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed by the board of directors of Kunming Pharmaceutical Group Co., Ltd. regarding the extension and revision of a public offering of A-shares, including detailed proposals on the issuance plan, use of proceeds, and related investment projects. It includes voting results of the board, references to shareholder meetings, and a feasibility study report for a specific investment project. The document also contains an auditor's verification report on the use of previously raised funds, which is a form of audit or assurance report related to fundraising activities. The content is focused on board decisions and proposals related to capital raising and investment projects, with detailed voting outcomes and plans to submit these proposals to the shareholders' meeting for approval. This aligns with the category of Capital/Financing Update (CAP), as it involves updates on company fundraising, financing activities, and capital structure changes. It is not a full annual or interim report, nor a simple announcement of a report publication. It is not a regulatory filing or a management report. The presence of detailed board resolutions and voting results on financing plans confirms the CAP classification with high confidence.
2012-11-01 Chinese
关于召开2012年第五次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice for a 2012 fifth extraordinary general meeting (临时股东大会) of Kunming Pharmaceutical Group Co., Ltd. It includes meeting time, location, agenda items, voting procedures including online voting, and proxy authorization forms. The content focuses on informing shareholders about the meeting and how to participate and vote on various proposals, including stock issuance and financing plans. There are no financial statements, earnings data, or management discussion of results. The document is not a report itself but a formal announcement and notice for a shareholders meeting. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2012-11-01 Chinese
七届一次监事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a supervisory board meeting of Kunming Pharmaceutical Group Co., Ltd. It includes voting results on various proposals related to share issuance and project changes, and mentions that these proposals will be submitted to the shareholders' meeting for approval. The document also contains personal resumes of key supervisory board members. The content is focused on board/supervisory decisions and appointments rather than financial results, audit opinions, or regulatory filings. It is not a full annual report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement for a shareholder meeting, but rather a board/management information announcement about supervisory board resolutions and appointments. The document length is short (1659 characters), but it contains substantive content about board decisions, not just a report publication announcement. Therefore, the best fitting category is Board/Management Information (MANG).
2012-11-01 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.